Novavax Inc (NVAX): Next-Year EPS Estimate 45.70%
As of 2026-11-06, Novavax Inc (NVAX) has a next-year EPS growth estimate of 45.70%. Featured in 4 EPS revision reports, most recently on 2026-10-14.
On 2026-11-06, analyst consensus for NVAX's next-year EPS growth shifted from 73.12% to 45.70% — a negative change of 27.42 percentage points. Current-year growth is projected at -116.07%.
What's Driving This
The provided data do not show an EPS estimate upgrade; instead, analysts lowered NVAX’s next-year EPS growth estimate from
Generated 2026-11-11 from news as of 2026-11-06
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 45.70%
- EPS growth this year
- -116.07%
- EPS next quarter (est)
- $0.18
- Last price
- $9.78
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-06 | 45.70% | -116.07% | $0.18 | $9.78 |
| 2026-11-05 | 73.12% | -117.84% | $0.16 | $9.78 |
| 2026-11-04 | 94.79% | -122.99% | -$0.35 | $10.65 |
| 2026-11-03 | 94.79% | -122.99% | -$0.35 | $9.68 |
| 2026-11-02 | 94.79% | -122.99% | -$0.35 | $9.53 |
| 2026-10-31 | 94.79% | -122.99% | -$0.35 | $10.08 |
| 2026-10-30 | 94.79% | -122.99% | -$0.35 | $10.08 |
| 2026-10-29 | 94.79% | -122.99% | -$0.35 | $10.47 |
| 2026-10-28 | 94.79% | -122.99% | -$0.35 | $10.32 |
| 2026-10-27 | 112.10% | -126.26% | -$0.34 | $10.02 |
| 2026-10-26 | 104.41% | -123.05% | -$0.22 | $9.40 |
| 2026-10-23 | 104.41% | -123.05% | -$0.22 | $9.70 |
| 2026-10-22 | 104.41% | -123.05% | -$0.22 | $9.99 |
| 2026-10-21 | 104.41% | -123.05% | -$0.22 | $11.01 |
| 2026-10-20 | 104.41% | -123.05% | -$0.22 | $11.43 |
| 2026-10-19 | 104.41% | -123.05% | -$0.22 | $10.82 |
| 2026-10-16 | 104.41% | -123.05% | -$0.22 | $11.26 |
| 2026-10-15 | 104.41% | -123.05% | -$0.22 | $12.82 |
| 2026-10-14 | 104.65% | -126.09% | -$0.22 | $12.64 |
| 2026-10-13 | 104.65% | -126.09% | -$0.22 | $12.82 |
| 2026-10-12 | 104.65% | -126.09% | -$0.22 | $12.66 |
| 2026-10-11 | 104.65% | -126.09% | -$0.22 | $12.75 |
| 2026-10-10 | 104.65% | -126.09% | -$0.22 | $12.75 |
| 2026-10-09 | 104.65% | -126.09% | -$0.22 | $12.75 |
| 2026-10-08 | 97.29% | -128.75% | -$0.24 | $11.01 |
| 2026-10-07 | 97.29% | -128.75% | -$0.24 | $11.22 |
| 2026-10-06 | 77.26% | -128.75% | -$0.24 | $11.32 |
| 2026-10-05 | 79.60% | -128.25% | -$0.23 | $12.56 |
| 2026-10-04 | 79.60% | -128.25% | -$0.23 | $10.46 |
| 2026-10-03 | 79.60% | -128.25% | -$0.23 | $10.46 |
Reports Featuring NVAX
Recent News
- Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector VolatilityInvestorsHub
- Pandemic Panic Is Back on Wall Street. What to Know About the Russian Plague Scare.Barrons.com
- Novavax, Moderna stocks fall after WHO calls plague risk 'low'Yahoo Finance
- Novavax Sinks 12% as WHO Calls Plague Risk Very LowTIKR
- Activist investor revives campaign to overhaul Novavax boardBioPharma Dive
- Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & DevelopmentPR Newswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Novavax Inc's next-year EPS growth estimate?▾
As of 2026-11-06, Novavax Inc (NVAX) has a next-year EPS growth estimate of 45.70%, based on analyst consensus.
When was the latest EPS estimate revision for NVAX?▾
The most recent revision occurred on 2026-11-06, when analysts adjusted the next-year EPS growth estimate from 73.12% to 45.70%.
What sector and industry does Novavax Inc belong to?▾
Novavax Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. NVAX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Novavax Inc (NVAX) appears here because it was detected by our daily top-EPS-revision-performer screen.